Roche has announced a $50 billion U.S. investment over five years, including anew 900,000-square-foot manufacturing facility for next-generation weight lossmedications and expansions in gene therapy and glucose monitoring deviceproduction, in response to persistent threats of U.S. pharmaceutical tariffs andshifting global supply chain risks. This move will add approximately 1,000 jobs toRoche's current U.S. workforce of over 25,000 across 24 sites, and willsignificantly boost R&D capabilities in multiple states, expanding on a newlydisclosed cardiovascular, renal, and metabolism R&D center in Massachusetts.

Pfizer CEO Albert Bourla said in a recent speech thatuncertainty over President Trump's planned pharmaceuticaltariffs is already costing the company $150 million and includedin its full-year guidance, is deterring further U.S. manufacturingand R&D investments. He added that the newly imposed globalminimum tax of about 15% has somewhat reduced incentives tooffshore production but stressed the U.S. still needs clearertariff policies or cuts to spur "tremendous" domesticinvestment. Although Pfizer maintained its earnings outlook,Bourla cautioned that any additional trade-policy shifts couldraise costs and force a reevaluation of its R&D expansion plans.

Several major pharmaceutical manufacturers are reshaping cost structures andproduction footprints in response to escalating tariff pressures. BMS recentlybuilt a "cushion" into its planning to address tariffs and potential FDArestructuring, raising its cost-cut target to $2 billion by 2027 as it leans onlaunches like Cobenfy to offset aging blockbusters such as Eliquis. Merck took adirect $200 million hit from levies between the U.S. and China, trimmed its 2025EPS outlook and is investing $21 billion in U.S. manufacturing through 2028 toshield Keytruda from future trade barriers and its impending patent cliff.

AbbVie recently announced plans to invest $10 billion in the U.S. through 2035,partly to build four new domestic manufacturing facilities in response topotential pharmaceutical import tariffs and shifting trade policy. While AbbVie'srevenues in the first quarter rose by 8.4% year-over-year to $13.34 billion, ledby Skyrizi's $3.43 billion and Rinvoq's 57% growth to $1.7 billion, sales of itsformer blockbuster, Humira, fell by 50% to $1.12 billion due to biosimilarcompetition through loss of exclusivity.

A new industry-commissioned report by Ernst & Young revealed thatimposing a 25% tariff on pharmaceutical imports could elevate annualU.S. drug expenditures by nearly $51 billion, potentially increasing pricesby as much as 12.9% for American consumers. The United Statesimported $203 billion worth of pharmaceuticals in 2023, with 73% ofimports from European nations, primarily Ireland, Germany, andSwitzerland; around 30% of these imports consisted of ingredients fordomestic manufacturing. Additionally, tariffs would raise domesticproduction costs by 4.1%, hurting global competitiveness and potentiallyendangering some of the industry's 490,000 export-related jobs.

Novartis CEO Vas Narasimhan warned in a recent speech that adopting a "MostFavored Nations" rule to align U.S. drug prices with lower international rateswould force pharma companies to reassess their medium-to-long term outlookand risk devastating R&D investment. The company has already pledged $23billion over five years to U.S. manufacturing, aiming for 100% of key productsproduced domestically, and downplayed tariff impacts compared with pricingthreats. Narasimhan and peers are urging the EU to raise drug prices, notingthat capped growth, low launch prices, and penalized indications have led to30% of new medicines being delayed or not launched in Europe.